Edition:
United States

FibroGen Inc (FGEN.OQ)

FGEN.OQ on NASDAQ Stock Exchange Global Select Market

60.55USD
16 Aug 2018
Change (% chg)

-- (--)
Prev Close
$60.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
152,645
52-wk High
$68.15
52-wk Low
$40.30

Chart for

About

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.... (more)

Overall

Beta: 1.86
Market Cap(Mil.): $5,032.22
Shares Outstanding(Mil.): 83.52
Dividend: --
Yield (%): --

Financials

  FGEN.OQ Industry Sector
P/E (TTM): -- 99.04 30.20
EPS (TTM): -0.87 -- --
ROI: -11.36 3.31 12.77
ROE: -19.15 2.31 14.92

BRIEF-FibroGen Reports Q1 Loss Per Share $0.50

* Q1 EARNINGS PER SHARE VIEW $-0.51 -- THOMSON REUTERS I/B/E/S

May 09 2018

BRIEF-Fibrogen Inc CEO's 2017 Compensation Was $7.1 Million

* FIBROGEN INC SAYS CEO THOMAS B. NEFF'S 2017 TOTAL COMPENSATION WAS $7.1 MILLION VERSUS $5.2 MILLION IN 2016 – SEC FILING Source text (https://bit.ly/2Hpk39x) Further company coverage:

Apr 24 2018

BRIEF-FibroGen Gets FDA Fast Track Designation For Its Pancreatic Cancer Treatment

* UPDATE - FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER

Mar 01 2018

BRIEF-Fibrogen Granted Fast Track Designation By U.S. FDA For Pamrevlumab Treatment Of Patients

* FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 01 2018

BRIEF-FibroGen Q4 Loss Per Share $0.27

* FIBROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 27 2018

Earnings vs. Estimates